Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Zhejiang Haichang Biotech Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07494435CT.gov Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | — | Not Yet Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07075120CT.gov Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | — | Recruiting | — | — | — |
NCT07219459CT.gov Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure | — | Recruiting | — | — | — |
NCT07166406CT.gov Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | — | Recruiting | — | — | — |
NCT07482059CT.gov A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07176650CT.gov Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
NCT07147101CT.gov Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | Recruiting | — | — | — |
NCT07376707CT.gov A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors | — | Recruiting | — | — | — |
Show 67 more trialsShow fewer
NCT06841185CT.gov A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06422403CT.gov A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | — | Recruiting | — | — | — |
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT05223816CT.gov An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | — | Recruiting | — | — | — |
NCT06034860CT.gov Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | — | Terminated | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05039736CT.gov A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | — | Withdrawn | — | — | — |
NCT05199285CT.gov A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | — | Terminated | — | — | — |
NCT05257590CT.gov CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05337137CT.gov A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | — | Completed | — | — | — |
NCT04965714CT.gov Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | — | Withdrawn | — | — | — |
NCT05220722CT.gov Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | — | Terminated | — | — | — |
NCT05302921CT.gov Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | — | Completed | — | — | — |
NCT06354387CT.gov Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | — | Completed | — | — | — |
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT05178043CT.gov GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04658147CT.gov Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | — | Active Not Recruiting | — | — | — |
NCT04912765CT.gov Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | — | Recruiting | — | — | — |
NCT04567615CT.gov A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | — | Completed | — | — | — |
NCT04380545CT.gov Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | — | Recruiting | — | — | — |
NCT04823403CT.gov Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04114136CT.gov Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT04340193CT.gov A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer | — | Completed | — | — | — |
NCT04472767CT.gov Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04310709CT.gov Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04170556CT.gov Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | — | Completed | — | — | — |
NCT04123379CT.gov Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT04039607CT.gov A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04050462CT.gov Nivolumab Combined With BMS-986253 in HCC Patients | — | Terminated | — | — | — |
NCT03781960CT.gov Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT03785210CT.gov Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | — | Terminated | — | — | — |
NCT03939975CT.gov Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC | — | Completed | — | — | — |
NCT03893695CT.gov Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | — | Completed | — | — | — |
NCT04268888CT.gov Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC | — | Suspended | — | — | — |
NCT03829436CT.gov TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | — | Completed | — | — | — |
NCT03682276CT.gov Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03655002CT.gov IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04233840CT.gov P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03510871CT.gov Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03735628CT.gov An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03695250CT.gov BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | — | Terminated | — | — | — |
NCT03630640CT.gov Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation | — | Completed | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03655613CT.gov APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | — | Terminated | — | — | — |
NCT03695952CT.gov A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03299946CT.gov Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT03439891CT.gov Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT04627012CT.gov Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT03222076CT.gov Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | — | Completed | — | — | — |
NCT03203304CT.gov Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | — | Terminated | — | — | — |
NCT03190174CT.gov Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | — | Completed | — | — | — |
NCT03071094CT.gov A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT03259867CT.gov Combination of TATE and PD-1 Inhibitor in Liver Cancer | — | Recruiting | — | — | — |
NCT03059147CT.gov Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT02859324CT.gov A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT02828124CT.gov A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | — | Terminated | — | — | — |
NCT02572687CT.gov A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | — | Completed | — | — | — |
NCT02705105CT.gov Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02435433CT.gov A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | — | Completed | — | — | — |
NCT02423343CT.gov A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02069041CT.gov A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer | — | Completed | — | — | — |
NCT02082210CT.gov A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT01658878CT.gov An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | — | Completed | — | — | — |
NCT01246986CT.gov A Study of LY2157299 in Participants With Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Zhejiang Haichang Biotech Co., Ltd. | P3 | BB · 65 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →